STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 3,240 Shares of Stock

STAAR Surgical Company (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 3,240 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was purchased at an average price of $21.94 per share, for a total transaction of $71,085.60. Following the completion of the acquisition, the insider owned 15,426,144 shares in the company, valued at $338,449,599.36. This represents a 0.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, January 7th, Broadwood Partners, L.P. purchased 66,467 shares of STAAR Surgical stock. The shares were purchased at an average cost of $22.00 per share, for a total transaction of $1,462,274.00.
• On Tuesday, January 6th, Broadwood Partners, L.P. bought 336,946 shares of STAAR Surgical stock. The stock was acquired at an average price of $21.62 per share, for a total transaction of $7,284,772.52.
• On Wednesday, November 19th, Broadwood Partners, L.P. purchased 309,132 shares of STAAR Surgical stock. The shares were bought at an average price of $26.42 per share, with a total value of $8,167,267.44.
• On Friday, November 21st, Broadwood Partners, L.P. purchased 797,486 shares of STAAR Surgical stock. The shares were purchased at an average cost of $27.86 per share, for a total transaction of $22,217,959.96.
• On Thursday, November 20th, Broadwood Partners, L.P. bought 393,382 shares of STAAR Surgical stock. The shares were acquired at an average price of $27.14 per share, with a total value of $10,676,387.48.

STAAR Surgical Trading Up 1.4%

STAA opened at $22.50 on Friday. The company has a 50 day moving average of $25.09 and a 200 day moving average of $24.37. STAAR Surgical Company has a 12 month low of $13.50 and a 12 month high of $30.81. The company has a market cap of $1.12 billion, a PE ratio of -11.54 and a beta of 1.00.

Institutional Trading of STAAR Surgical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Broadwood Capital Inc. grew its position in STAAR Surgical by 8.5% in the 2nd quarter. Broadwood Capital Inc. now owns 13,519,491 shares of the medical instruments supplier’s stock valued at $226,857,000 after acquiring an additional 1,064,227 shares during the last quarter. Soleus Capital Management L.P. grew its stake in shares of STAAR Surgical by 16.5% during the second quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier’s stock worth $50,084,000 after acquiring an additional 421,840 shares during the last quarter. Yunqi Capital Ltd grew its position in STAAR Surgical by 3.7% during the 3rd quarter. Yunqi Capital Ltd now owns 2,500,061 shares of the medical instruments supplier’s stock worth $67,177,000 after purchasing an additional 88,773 shares during the last quarter. Resona Asset Management Co. Ltd. increased its position in shares of STAAR Surgical by 11.6% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 2,421,836 shares of the medical instruments supplier’s stock valued at $40,746,000 after acquiring an additional 252,218 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new position in shares of STAAR Surgical in the third quarter worth about $48,729,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on STAA shares. BTIG Research reaffirmed a “neutral” rating on shares of STAAR Surgical in a research report on Tuesday. Piper Sandler restated a “neutral” rating on shares of STAAR Surgical in a research note on Monday, October 27th. Canaccord Genuity Group lifted their price target on shares of STAAR Surgical from $28.00 to $30.75 and gave the stock a “hold” rating in a research note on Tuesday, December 9th. Weiss Ratings restated a “sell (d)” rating on shares of STAAR Surgical in a research note on Wednesday, October 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday. Ten equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $23.42.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.